Free Trial
NYSE:ANRO

Alto Neuroscience (ANRO) Stock Price, News & Analysis

$12.92
+1.16 (+9.86%)
(As of 05/24/2024 ET)
Today's Range
$11.77
$13.63
50-Day Range
$11.73
$17.90
52-Week Range
$11.68
$24.00
Volume
98,307 shs
Average Volume
96,814 shs
Market Capitalization
$347.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.33

Alto Neuroscience MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
150.3% Upside
$32.33 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$100,614 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.93) to ($3.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

627th out of 923 stocks

Pharmaceutical Preparations Industry

281st out of 423 stocks

ANRO stock logo

About Alto Neuroscience Stock (NYSE:ANRO)

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

ANRO Stock Price History

ANRO Stock News Headlines

Analysts bullish on Alto Neuroscience
Alto Neuroscience Inc ANRO
Alto Neuroscience Inc (ANRO)
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. (ANRO)
See More Headlines
Receive ANRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/26/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.33
High Stock Price Target
$33.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+150.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$210,000.00
Book Value
$7.18 per share

Miscellaneous

Free Float
N/A
Market Cap
$347.29 million
Optionable
N/A
Beta
N/A
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Amit Etkin M.D. (Age 47)
    Ph.D., Founder, Chairman of the Board, CEO & President
    Comp: $705.65k
  • Mr. Nicholas C. Smith (Age 35)
    CFO & Secretary
    Comp: $624.12k
  • Mr. Adam Savitz M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $579.57k
  • Ms. Melissa Berman (Age 44)
    Vice President of Finance & Accounting
  • Ms. Erin R. McQuade J.D. (Age 49)
    General Counsel & Chief Administrative Officer
  • Ms. Jessica Powell (Age 49)
    Chief Development Officer
  • Mr. Fadi Abdel M.D. (Age 45)
    Senior Vice President of Innovation

ANRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Alto Neuroscience stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alto Neuroscience in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANRO shares.
View ANRO analyst ratings
or view top-rated stocks.

What is Alto Neuroscience's stock price target for 2024?

5 brokers have issued 1-year price targets for Alto Neuroscience's stock. Their ANRO share price targets range from $32.00 to $33.00. On average, they expect the company's stock price to reach $32.33 in the next twelve months. This suggests a possible upside of 150.3% from the stock's current price.
View analysts price targets for ANRO
or view top-rated stocks among Wall Street analysts.

How have ANRO shares performed in 2024?

Alto Neuroscience's stock was trading at $21.80 at the beginning of the year. Since then, ANRO stock has decreased by 40.7% and is now trading at $12.92.
View the best growth stocks for 2024 here
.

When is Alto Neuroscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our ANRO earnings forecast
.

What ETF holds Alto Neuroscience's stock?

iShares Neuroscience and Healthcare ETF holds 1,308 shares of ANRO stock, representing 0.54% of its portfolio.

When did Alto Neuroscience IPO?

Alto Neuroscience (ANRO) raised $129 million in an IPO on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share.

When does Alto Neuroscience's lock-up period expire?

Alto Neuroscience's lock-up period expires on Wednesday, July 31st. Alto Neuroscience had issued 8,040,000 shares in its public offering on February 2nd. The total size of the offering was $128,640,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who are Alto Neuroscience's major shareholders?

Alto Neuroscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (5.15%), Price T Rowe Associates Inc. MD (2.37%), Vanguard Group Inc. (1.99%), Jennison Associates LLC (1.71%), Artal Group S.A. (1.30%) and AWM Investment Company Inc. (1.11%). Insiders that own company stock include Nicholas Conrad Smith and Wave Global Lp Alpha.
View institutional ownership trends
.

How do I buy shares of Alto Neuroscience?

Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ANRO) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners